NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $340,694 | -21.6% | 17,726 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $434,580 | -28.6% | 17,096 | +1.5% | 0.00% | -25.0% |
| Q1 2023 | $608,947 | -6.9% | 16,845 | +2.0% | 0.00% | -20.0% |
| Q4 2022 | $653,756 | -15.3% | 16,509 | -0.4% | 0.01% | -16.7% |
| Q3 2022 | $772,000 | +7.8% | 16,570 | +1.4% | 0.01% | +20.0% |
| Q2 2022 | $716,000 | -42.4% | 16,336 | -4.9% | 0.01% | -28.6% |
| Q1 2022 | $1,243,000 | -16.6% | 17,179 | -6.6% | 0.01% | 0.0% |
| Q4 2021 | $1,491,000 | -32.4% | 18,387 | -2.9% | 0.01% | -41.7% |
| Q3 2021 | $2,204,000 | -31.4% | 18,937 | -2.3% | 0.01% | +9.1% |
| Q2 2021 | $3,214,000 | +16.2% | 19,388 | -2.2% | 0.01% | +10.0% |
| Q1 2021 | $2,765,000 | -19.2% | 19,819 | +0.3% | 0.01% | -23.1% |
| Q4 2020 | $3,421,000 | +22.3% | 19,766 | -1.6% | 0.01% | 0.0% |
| Q3 2020 | $2,797,000 | +14.0% | 20,079 | -2.2% | 0.01% | +8.3% |
| Q2 2020 | $2,453,000 | +38.6% | 20,535 | +16.0% | 0.01% | +20.0% |
| Q1 2020 | $1,770,000 | -19.6% | 17,708 | -5.5% | 0.01% | +11.1% |
| Q4 2019 | $2,202,000 | +35.6% | 18,730 | -0.8% | 0.01% | +28.6% |
| Q3 2019 | $1,624,000 | +33.2% | 18,887 | +0.5% | 0.01% | +40.0% |
| Q2 2019 | $1,219,000 | +5.1% | 18,796 | +1.3% | 0.01% | +25.0% |
| Q1 2019 | $1,160,000 | +55.7% | 18,563 | -3.1% | 0.00% | +33.3% |
| Q4 2018 | $745,000 | -32.3% | 19,165 | -0.8% | 0.00% | -25.0% |
| Q3 2018 | $1,101,000 | -27.3% | 19,313 | +1.8% | 0.00% | -20.0% |
| Q2 2018 | $1,514,000 | -2.5% | 18,964 | +5.8% | 0.01% | 0.0% |
| Q1 2018 | $1,553,000 | +20.5% | 17,916 | -4.0% | 0.01% | +25.0% |
| Q4 2017 | $1,289,000 | -23.6% | 18,667 | +0.5% | 0.00% | -33.3% |
| Q3 2017 | $1,688,000 | +32.0% | 18,579 | +8.1% | 0.01% | +20.0% |
| Q2 2017 | $1,279,000 | -6.2% | 17,190 | +18.1% | 0.01% | 0.0% |
| Q1 2017 | $1,364,000 | +35.9% | 14,553 | +5.3% | 0.01% | +25.0% |
| Q4 2016 | $1,004,000 | -99.9% | 13,814 | -0.3% | 0.00% | -33.3% |
| Q3 2016 | $1,445,906,000 | +41.7% | 13,851 | +0.2% | 0.01% | +50.0% |
| Q2 2016 | $1,020,101,000 | +88.2% | 13,830 | +43.5% | 0.00% | +100.0% |
| Q1 2016 | $542,000,000 | -9.5% | 9,638 | +8.5% | 0.00% | 0.0% |
| Q4 2015 | $599,000,000 | +144936.3% | 8,880 | -0.2% | 0.00% | 0.0% |
| Q3 2015 | $413,000 | -99.9% | 8,896 | +0.1% | 0.00% | 0.0% |
| Q2 2015 | $477,623,000 | +96.9% | 8,886 | +75.6% | 0.00% | +100.0% |
| Q1 2015 | $242,574,000 | +23.9% | 5,061 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $195,709,000 | – | 5,061 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |